Repligen (RGEN) Competitors

Biogen (NASDAQ:BIIB) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

Does the media refer more to BIIB or RGEN?

In the previous week, Biogen had 27 more articles in the media than Repligen. MarketBeat recorded 40 mentions for Biogen and 13 mentions for Repligen. Biogen's average media sentiment score of 0.95 beat Repligen's score of 0.79 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	21 Very Positive mention(s)	2 Positive mention(s)	14 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer BIIB or RGEN?

Biogen presently has a consensus target price of $188.48, suggesting a potential upside of 50.08%. Repligen has a consensus target price of $172.83, suggesting a potential upside of 38.96%. Given Biogen's higher possible upside, equities research analysts clearly believe Biogen is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	0 Sell rating(s)	20 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.38
Repligen	0 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.69

Do institutionals and insiders have more ownership in BIIB or RGEN?

87.9% of Biogen shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 1.2% of Repligen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has stronger earnings and valuation, BIIB or RGEN?

Biogen has higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.68B	1.90	$1.63B	$10.13	12.40
Repligen	$634.44M	11.01	-$25.51M	-$0.45	-276.40

Which has more risk and volatility, BIIB or RGEN?

Biogen has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500. Comparatively, Repligen has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500.

Is BIIB or RGEN more profitable?

Biogen has a net margin of 15.07% compared to Repligen's net margin of -3.93%. Biogen's return on equity of 14.03% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	15.07%	14.03%	8.32%
Repligen	-3.93%	4.53%	3.17%

Summary

Biogen beats Repligen on 11 of the 16 factors compared between the two stocks.